However, there are positive signs that demonstrate Icon’s resilience and support its narrow moat rating. Icon’s backlog at quarter-end was $24.7 billion, an increase of 8.3% from the fourth ...
We are closely watching nascent trends in drug development ... However, there are positive signs that demonstrate Icon’s resilience. Icon’s backlog at the end of 2024 was $24.7 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback